Mainz Biomed (NASDAQ:MYNZ – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($3.60) per share and revenue of $0.25 million for the quarter.
Mainz Biomed Trading Down 10.3 %
Shares of Mainz Biomed stock opened at $3.21 on Tuesday. The business’s 50-day moving average price is $5.37 and its 200-day moving average price is $7.25. The firm has a market capitalization of $6.42 million, a PE ratio of -0.05 and a beta of 0.33. Mainz Biomed has a 12 month low of $2.88 and a 12 month high of $45.20.
Analysts Set New Price Targets
Separately, Maxim Group started coverage on shares of Mainz Biomed in a research note on Friday, February 14th. They set a “buy” rating and a $14.00 price target on the stock.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
See Also
- Five stocks we like better than Mainz Biomed
- How to Use the MarketBeat Dividend Calculator
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- The How And Why of Investing in Oil Stocks
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
